Clinical Study
Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients
Table 1
Demographic and examination data of both groups.
| | | Group A | Group B | value | (Chloroquine group) | (Control group) |
| Age in years | Mean ± SD | 49.95 ± 7.78 | 51 ± 7.38 | 0.49 | BCVA (LogMAR) | Mean ± SD | 0.3688 ± 0.307 | 0.4825 ± 0.343 | 0.122 | Color vision (normal/defective) | Normal | (34/6) | (36/4) | 0.499 | Disease duration in years | Mean ± SD | 8.1 ± 7.67 | N/A | — | Chloroquine treatment Duration in years | Mean ± SD | 3.8 ± 2.79 | N/A | — | Chloroquine cumulative dose (grams) | Mean ± SD | 346.6 ± 225.24 | N/A | — |
|
|
Independent samples student’s -test. Chi square test.
|